home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Genetic News | search  
 

"Costimulatory” Protein On T Cells Plays A Key Role In Acute/Chronic Organ Rejection

 
  July, 2 2001 2:18
your information resource in human molecular genetics
 
     
Cracking organ rejection

Organ transplants could save the lives of many patients, but the ultimate rejection of the organ remains a stubborn problem. The immune system is the main culprit because it is designed to destroy invading microorganisms or other foreign matter. Immune cells recognize transplanted organs as foreign because of minor genetic differences between the donor and recipient that result in a destructive attack on the organ. Chemical immunosuppressants such as cyclosporin A, which dampen-down the immune system, can prevent short-term or “acute rejection” in the first year after transplantation. However, long-term or “chronic rejection” beyond the one-year mark remains high, despite continuous administration of these drugs.

The mechanisms behind chronic rejection are still obscure, making the development of new therapies to specifically induce long-term acceptance difficult. In the July issue of Nature Immunology (Vol. 2, No. 7, pages 591-596), scientists at Millenium Pharmaceuticals in Boston explored the role of a “costimulatory” protein on T cells called ICOS. They found ICOS plays a key role in both acute and chronic rejection. Using a mouse transplant model, they show that two weeks of ICOS blockade and cyclosporin A treatment not only prevents acute rejection but also leads to long-term acceptance of the transplant. This basic investigation into the mechanism of rejection has thus provided a promising new approach that can be considered for the prolongation of transplants.

A News & Views on this article was written by Jeffrey A. Bluestone of the University of California, San Francisco, Head of the National Immune Tolerance Network (pages 573-574).

Wayne W. Hancock
Millenium Pharmaceuticals, Inc.
Biotherapeutics
75 Sidney Street
Cambridge, MA 02139
UNITED STATES
Tel: (+1) 617-551-3637
Fax: (+1) 617-679-7071
whancock@mpi.com

Jeffrey A. Bluestone
University of California - San Francisco
UCSF Diabetes Center
513 Parnassus Ave.
Room HSW 1114, Box 0540
San Francisco, CA 94143-0540
UNITED STATES
Tel: (+1) 415-514-1683
Fax: (+1) 415-476-1660
jbluest@diabetes.ucsf.edu

(C) Nature Immunology press release.


Message posted by: Trevor M. D'Souza

print this article mail this article
Bookmark and Share this page (what is this?)

Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.

Use the links below to share this article on the social bookmarking site of your choice.

Read more about social bookmarking at Wikipedia - Social Bookmarking

Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2016 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.